ORAGENICS INC (OGEN) Fundamental Analysis & Valuation

NYSEARCA:OGEN • US6840236094

0.923 USD
+0.02 (+2.57%)
Last: Mar 9, 2026, 11:58 AM

This OGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to OGEN. OGEN was compared to 519 industry peers in the Biotechnology industry. OGEN may be in some trouble as it scores bad on both profitability and health. OGEN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. OGEN Profitability Analysis

1.1 Basic Checks

  • In the past year OGEN has reported negative net income.
  • In the past year OGEN has reported a negative cash flow from operations.
  • OGEN had negative earnings in each of the past 5 years.
  • In the past 5 years OGEN always reported negative operating cash flow.
OGEN Yearly Net Income VS EBIT VS OCF VS FCFOGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -717.68%, OGEN is doing worse than 94.99% of the companies in the same industry.
Industry RankSector Rank
ROA -717.68%
ROE N/A
ROIC N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OGEN Yearly ROA, ROE, ROICOGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K -6K

1.3 Margins

  • OGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGEN Yearly Profit, Operating, Gross MarginsOGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

0

2. OGEN Health Analysis

2.1 Basic Checks

  • OGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, OGEN has more shares outstanding
  • Compared to 5 years ago, OGEN has more shares outstanding
  • Compared to 1 year ago, OGEN has a worse debt to assets ratio.
OGEN Yearly Shares OutstandingOGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
OGEN Yearly Total Debt VS Total AssetsOGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • Based on the Altman-Z score of -228.61, we must say that OGEN is in the distress zone and has some risk of bankruptcy.
  • OGEN has a Altman-Z score of -228.61. This is amonst the worse of the industry: OGEN underperforms 94.99% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -228.61
ROIC/WACCN/A
WACC8.39%
OGEN Yearly LT Debt VS Equity VS FCFOGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 0.87 indicates that OGEN may have some problems paying its short term obligations.
  • The Current ratio of OGEN (0.87) is worse than 87.48% of its industry peers.
  • OGEN has a Quick Ratio of 0.87. This is a bad value and indicates that OGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.87, OGEN is doing worse than 87.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
OGEN Yearly Current Assets VS Current LiabilitesOGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

1

3. OGEN Growth Analysis

3.1 Past

  • OGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.49%, which is quite impressive.
  • OGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)78.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 15.02% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OGEN Yearly Revenue VS EstimatesOGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 20K 40K 60K 80K 100K
OGEN Yearly EPS VS EstimatesOGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -200 -400 -600 -800 -1K

1

4. OGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OGEN. In the last year negative earnings were reported.
  • Also next year OGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGEN Price Earnings VS Forward Price EarningsOGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGEN Per share dataOGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30 -40 -50

4.3 Compensation for Growth

  • OGEN's earnings are expected to grow with 25.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.35%
EPS Next 3Y25.6%

0

5. OGEN Dividend Analysis

5.1 Amount

  • OGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

OGEN Fundamentals: All Metrics, Ratios and Statistics

ORAGENICS INC

NYSEARCA:OGEN (3/9/2026, 11:58:33 AM)

0.923

+0.02 (+2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-12
Inst Owners7.03%
Inst Owner Change48.45%
Ins Owners0.4%
Ins Owner Change-0.03%
Market Cap3.85M
Revenue(TTM)N/A
Net Income(TTM)-10.57M
Analysts82.86
Price Target2.04 (121.02%)
Short Float %11.27%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-56.05
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -717.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -228.61
F-Score2
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.29%
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.76%
EBIT Next 3Y-28.26%
EBIT Next 5YN/A
FCF growth 1Y-3.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.92%
OCF growth 3YN/A
OCF growth 5YN/A

ORAGENICS INC / OGEN FAQ

What is the ChartMill fundamental rating of ORAGENICS INC (OGEN) stock?

ChartMill assigns a fundamental rating of 0 / 10 to OGEN.


Can you provide the valuation status for ORAGENICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ORAGENICS INC (OGEN). This can be considered as Overvalued.


What is the profitability of OGEN stock?

ORAGENICS INC (OGEN) has a profitability rating of 0 / 10.